NASDAQ:MDWD

MediWound - MDWD Stock Forecast, Price & News

$1.38

-0.01 (-0.72%)

(As of 10/3/2022 09:49 AM ET)

Add

Compare

Today's Range: $1.37
▼
$1.38
50-Day Range: $1.35
▼
$2.24
52-Week Range: $1.21
▼
$4.01

Volume: 1,200 shs
Average Volume: 115,866 shs
Market Capitalization: $45.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

MediWound MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 407.2% Upside
$7.00 Price Target
Short Interest: Healthy
0.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.17
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.44) to ($0.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

446th out of 1,093 stocks

Medicinals & Botanicals Industry

3rd out of 15 stocks

3.5

Analyst's Opinion

Consensus Rating
MediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, MediWound has a forecasted upside of 407.2% from its current price of $1.38.
Amount of Analyst Coverage
MediWound has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.40% of the float of MediWound has been sold short.
Short Interest Ratio / Days to Cover
MediWound has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in MediWound has recently decreased by 20.25%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MediWound does not currently pay a dividend.
Dividend Growth
MediWound does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MDWD.

3.4

News and Social Media Coverage

News Sentiment
MediWound has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for MediWound this week, compared to 3 articles on an average week.
Search Interest
1 people have searched for MDWD on MarketBeat in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MediWound insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 13.58% of the stock of MediWound is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MediWound are expected to grow in the coming year, from ($0.44) to ($0.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MediWound is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MediWound is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About MediWound (NASDAQ:MDWD) Stock

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MDWD Stock News Headlines

September 27, 2022 | americanbankingnews.com

MediWound (NASDAQ:MDWD) Coverage Initiated at StockNews.com

September 24, 2022 | marketwatch.com

MediWound Shares Slide Premarket After Stock Offerings >MDWD - MarketWatch

September 23, 2022 | nasdaq.com

Health Care Sector Update for 09/22/2022: LLY, LUNA, ISRG, MDWD - Nasdaq

September 22, 2022 | seekingalpha.com

Spero, HeartBeam top healthcare gainers; MediWound, Vincerx lead losers' pack - Seeking Alpha

September 22, 2022 | benzinga.com

Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday’s Mid-Day Session - A - Benzinga

September 22, 2022 | benzinga.com

Vericel to Present at the Ladenburg Thalmann Healthcare Conference - Vericel (NASDAQ:VCEL) - Benzinga

September 22, 2022 | benzinga.com

MediWound shares are trading lower after the company announced concurrent registered direct and private p - Benzinga

September 22, 2022 | globenewswire.com

MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million - GlobeNewswire

September 22, 2022 | finance.yahoo.com

MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million

September 20, 2022 | globenewswire.com

EMA Accepts MediWound's Application for Extended Indication - GlobeNewswire

September 20, 2022 | finance.yahoo.com

EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns

September 12, 2022 | globenewswire.com

MediWound's NexoBrid® Highlighted in 45 Posters and - GlobeNewswire

September 12, 2022 | benzinga.com

MediWound (NASDAQ:MDWD) – MediWound's NexoBrid® Highlighted in 45 Posters and Presentations at the 19th E - Benzinga

September 12, 2022 | finance.yahoo.com

MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress

September 8, 2022 | reuters.com

MDWD.P - Mediwound Ltd | Stock Price & Latest News | Reuters

September 8, 2022 | globenewswire.com

Enzymatic Debridement Market exhibiting a CAGR of 8.3 % and is expected to reach USD 680 Million by 2029 - GlobeNewswire

September 6, 2022 | globenewswire.com

Vericel to Present at the Morgan Stanley Global Healthcare and HC Wainwright Global Investment Conferences - GlobeNewswire

August 25, 2022 | reuters.com

MDWD.O - Mediwound Ltd | Stock Price & Latest News | Reuters

August 23, 2022 | finance.yahoo.com

IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum “Homi” Shamir to its Board of Directors - Yahoo Finance

August 15, 2022 | finance.yahoo.com

Things Look Grim For MediWound Ltd. (NASDAQ:MDWD) After Today's Downgrade

August 9, 2022 | investing.com

MediWound Misses Q2 EPS by 3c By Investing.com - Investing.com

August 9, 2022 | seekingalpha.com

MediWound Q2 Earnings Preview (NASDAQ:MDWD) - Seeking Alpha

August 9, 2022 | in.investing.com

MediWound Misses Q2 EPS by 3c By Investing.com - Investing.com India

August 9, 2022 | streetinsider.com

MediWound Enhances Its Board and Executive Leadership Team - StreetInsider.com

August 9, 2022 | globenewswire.com

MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates - GlobeNewswire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MDWD Company Calendar

Last Earnings: 8/09/2022
Today: 10/03/2022
Next Earnings (Estimated): 11/15/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medicinals & botanicals
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MDWD
CUSIP: N/A
CIK: 1593984
Web: www.mediwound.com
Phone: 972779714100
Fax: 972-77-971-4111
Employees: 77
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +407.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,550,000.00
Net Margins: -73.79%
Pretax Margin: -73.72%
Return on Equity: N/A
Return on Assets: -68.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.61
Quick Ratio: 1.42

Sales & Book Value

Annual Sales: $23.76 million
Price / Sales: 1.92
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.17) per share
Price / Book: -8.12

Miscellaneous

Outstanding Shares: 33,141,000
Free Float: N/A
Market Cap: $45.73 million
Optionable: Not Optionable
Beta: 1.09

Key Executives

Prof. Lior Rosenberg M.D. (Age 76)
Co-Founder & Medical Director
Comp: $398k

Mr. Boaz Gur-Lavie CPA (Age 48)
M.B.A., Chief Financial Officer
Comp: $309k

Mr. Yaron Meyer Adv. (Age 43)
Exec. VP, Gen. Counsel & Corp. Sec.
Comp: $240k

Dr. Ety Klinger (Age 60)
Chief R&D Officer
Comp: $344k

Mr. Ofer Gonen B.Sc. (Age 49)
Chief Exec. Officer

Mr. Tzvi Palash B.Sc. (Age 65)
M.Sc., Chief Operating Officer

Mr. Stephen T. Wills CPA (Age 65)
CPA, MST, Exec. Director

Dr. Robert J. Snyder CWS
D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDWD Stock - Frequently Asked Questions

Should I buy or sell MediWound stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings or view top-rated stocks.
What is MediWound's stock price forecast for 2022?: 3 brokerages have issued 1 year price objectives for MediWound's shares. Their MDWD share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 403.6% from the stock's current price.
View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts.
How have MDWD shares performed in 2022?: MediWound's stock was trading at $2.36 on January 1st, 2022. Since then, MDWD shares have decreased by 41.1% and is now trading at $1.39.
View the best growth stocks for 2022 here.
When is MediWound's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 15th 2022.
View our MDWD earnings forecast.

How were MediWound's earnings last quarter?: MediWound Ltd. (NASDAQ:MDWD) issued its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.03. The biopharmaceutical company had revenue of $4.67 million for the quarter, compared to the consensus estimate of $5.27 million. MediWound had a negative net margin of 73.79% and a negative trailing twelve-month return on equity of 3,540.43%.
What other stocks do shareholders of MediWound own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).
What is MediWound's stock symbol?: MediWound trades on the NASDAQ under the ticker symbol "MDWD."
How do I buy shares of MediWound?: Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MediWound's stock price today?: One share of MDWD stock can currently be purchased for approximately $1.39.
How much money does MediWound make?: MediWound (NASDAQ:MDWD) has a market capitalization of $46.06 million and generates $23.76 million in revenue each year. The biopharmaceutical company earns $-13,550,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.
How can I contact MediWound?: MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for the company is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111.

This page (NASDAQ:MDWD) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MediWound - MDWD Stock Forecast, Price & News

MediWound MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About MediWound (NASDAQ:MDWD) Stock

MDWD Stock News Headlines

MDWD Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MDWD Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™